loader
Please Wait
Applying Filters...

Seqens Seqens

X

List of Nilotinib NDC API suppliers/manufacturers & exporters

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Dr. Reddy's Laboratories Limited (1)

02 Dr.Reddy's Laboratories Limited (1)

03 Granules India Ltd (1)

04 Hetero Labs Limited (1)

05 MSN Laboratories Private Limited (3)

06 Natco Pharma Limited (1)

07 Pliva Croatia Ltd (2)

08 Sterling Pharma Solutions Limited (1)

09 Suzhou Lixin Pharmaceutical Co., Ltd. (1)

10 VALARY LAB PRIVATE LIMITED (1)

filter

01 NILOTINIB HYDROCHLORIDE (1)

02 NILOTINIB HYDROCHLORIDE ANHYDROUS (1)

03 Nilotinib (2)

04 Nilotinib Fumarate (1)

05 Nilotinib Hydrochloride (2)

06 Nilotinib Hydrochloride (Monohydrate) (1)

07 Nilotinib Hydrochloride Dihydrate (1)

08 Nilotinib Hydrochloride Monohydrate (2)

09 Nilotinib Hydrochloride Sesquihydrate (1)

10 nILOTINIB HYDROCHLORIDE MONOHYDRATE (1)

filter

01 China (1)

02 Croatia (2)

03 India (8)

04 United Kingdom (1)

05 Blank (1)

URL Supplier Web Content
Nilotinib Hydrochloride Monohydrate
POWDER (600g/600g)
BULK INGREDIENT
62207-984
2022-09-30
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib Hydrochloride Sesquihydrate
POWDER (1kg/kg)
BULK INGREDIENT
54893-0111
2021-03-19
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib Hydrochloride (Monohydrate)
POWDER (1kg/kg)
BULK INGREDIENT
54893-0075
2018-03-29
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib
POWDER (1kg/kg)
BULK INGREDIENT
54893-0069
2018-01-22
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib Fumarate
POWDER (100kg/100kg)
BULK INGREDIENT
11722-070
2019-08-26
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
NILOTINIB HYDROCHLORIDE ANHYDROUS
POWDER (1kg/kg)
BULK INGREDIENT
11722-019
2010-04-23
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib Hydrochloride
POWDER (350kg/350kg)
BULK INGREDIENT
50384-6700
2023-07-03
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Nilotinib Hydrochloride Monohydrate
POWDER (1kg/kg)
BULK INGREDIENT
29930-008
2022-10-31
2024-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for 923288-95-3 / Nilotinib API manufacturers, exporters & distributors?

Nilotinib manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Nilotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nilotinib manufacturer or Nilotinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nilotinib manufacturer or Nilotinib supplier.

PharmaCompass also assists you with knowing the Nilotinib API Price utilized in the formulation of products. Nilotinib API Price is not always fixed or binding as the Nilotinib Price is obtained through a variety of data sources. The Nilotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Nilotinib

Synonyms

923288-95-3, Nilotinib hydrochloride anhydrous, Nilotinib hcl, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide hydrochloride, Nilotinib (hydrochloride), K37n7byx3x

Cas Number

923288-95-3

Unique Ingredient Identifier (UNII)

K37N7BYX3X

About Nilotinib

Nilotinib Hydrochloride Anhydrous is the hydrochloride salt of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.

Nilotinib Manufacturers

A Nilotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nilotinib, including repackagers and relabelers. The FDA regulates Nilotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nilotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Nilotinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Nilotinib Suppliers

A Nilotinib supplier is an individual or a company that provides Nilotinib active pharmaceutical ingredient (API) or Nilotinib finished formulations upon request. The Nilotinib suppliers may include Nilotinib API manufacturers, exporters, distributors and traders.

click here to find a list of Nilotinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Nilotinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nilotinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Nilotinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Nilotinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Nilotinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nilotinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Nilotinib suppliers with NDC on PharmaCompass.

Nilotinib Manufacturers | Traders | Suppliers

Nilotinib Manufacturers, Traders, Suppliers 1
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Post Enquiry
POST ENQUIRY